Literature DB >> 19018610

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Brad Spellberg1, George H Talbot, Eric P Brass, John S Bradley, Helen W Boucher, David N Gilbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19018610      PMCID： PMC2827629     

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  69 in total

1.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

2.  Pneumoccocal pneumonia treated with penicillin and aspirin.

Authors:  R G PETERSDORF; L E CLUFF; P D HOEPRICH; F T HOPKINS; W P MCCANN
Journal:  Bull Johns Hopkins Hosp       Date:  1957-07

Review 3.  Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.

Authors:  Daphna Shefet; Eyal Robenshtok; Mical Paul; Leonard Leibovici
Journal:  Arch Intern Med       Date:  2005-09-26

4.  The effect of antibiotics (penicillin, aureomycin, and terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia; a comparison with other methods of therapy.

Authors:  H F DOWLING; M H LEPPER
Journal:  Am J Med Sci       Date:  1951-10       Impact factor: 2.378

5.  Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy.

Authors:  J D Smilack; W W Burgin; W L Moore; J P Sanford
Journal:  JAMA       Date:  1974-05-06       Impact factor: 56.272

6.  Therapeutic effect of doxycycline upon Mycoplasma pneumoniae pneumonia.

Authors:  W M Gooch; W J Mogabgab
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

7.  Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.

Authors:  M A Kelley; D J Weber; P Gilligan; M S Cohen
Journal:  Clin Infect Dis       Date:  2000-10-13       Impact factor: 9.079

8.  Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system.

Authors:  K L Kahn; W H Rogers; L V Rubenstein; M J Sherwood; E J Reinisch; E B Keeler; D Draper; J Kosecoff; R H Brook
Journal:  JAMA       Date:  1990-10-17       Impact factor: 56.272

Review 9.  Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.

Authors:  Paul G Ambrose
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

Review 10.  Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?

Authors:  George H Talbot
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079
View more
  17 in total

Review 1.  Assessment of bias in outcomes reported in trials on pneumonia: a systematic review.

Authors:  T Avni; S Shiber-Ofer; L Leibovici; M Paul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-19       Impact factor: 3.267

2.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

3.  Combating antimicrobial resistance: policy recommendations to save lives.

Authors:  Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 4.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

Review 5.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

6.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

Review 7.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

8.  Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.

Authors:  Dirkie J J van Rensburg; Reury-Perng Perng; Ismail H Mitha; Andrè J Bester; Joseph Kasumba; Ren-Guang Wu; Ming-Lin Ho; Li-Wen Chang; David T Chung; Yu-Ting Chang; Chi-Hsin R King; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 9.  Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Authors:  Brad Spellberg; George H Talbot; Helen W Boucher; John S Bradley; David Gilbert; W Michael Scheld; John Edwards; John G Bartlett
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

10.  Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.

Authors:  Julia A Bielicki; Wolfgang Stöhr; Sam Barratt; David Dunn; Nishdha Naufal; Damian Roland; Kate Sturgeon; Adam Finn; Juan Pablo Rodriguez-Ruiz; Surbhi Malhotra-Kumar; Colin Powell; Saul N Faust; Anastasia E Alcock; Dani Hall; Gisela Robinson; Daniel B Hawcutt; Mark D Lyttle; Diana M Gibb; Mike Sharland
Journal:  JAMA       Date:  2021-11-02       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.